WO2001041782A3 - Method for administering a cytokine to the central nervous system and the lymphatic system - Google Patents

Method for administering a cytokine to the central nervous system and the lymphatic system Download PDF

Info

Publication number
WO2001041782A3
WO2001041782A3 PCT/US2000/033220 US0033220W WO0141782A3 WO 2001041782 A3 WO2001041782 A3 WO 2001041782A3 US 0033220 W US0033220 W US 0033220W WO 0141782 A3 WO0141782 A3 WO 0141782A3
Authority
WO
WIPO (PCT)
Prior art keywords
central nervous
nervous system
cytokine
administering
disorders
Prior art date
Application number
PCT/US2000/033220
Other languages
French (fr)
Other versions
WO2001041782A2 (en
Inventor
William H Ii Frey
Original Assignee
Chiron Corp
William H Ii Frey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, William H Ii Frey filed Critical Chiron Corp
Priority to EP00984018A priority Critical patent/EP1237567B1/en
Priority to AU20698/01A priority patent/AU783208B2/en
Priority to CA002393688A priority patent/CA2393688A1/en
Priority to JP2001543126A priority patent/JP2003516360A/en
Priority to IL15010900A priority patent/IL150109A0/en
Priority to AT00984018T priority patent/ATE300952T1/en
Priority to DE60021760T priority patent/DE60021760T2/en
Publication of WO2001041782A2 publication Critical patent/WO2001041782A2/en
Publication of WO2001041782A3 publication Critical patent/WO2001041782A3/en
Priority to NO20022731A priority patent/NO20022731L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Abstract

The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a method of delivery can be useful in the treatment of central nervous system disorders, brain disorders, proliferative, viral, and/or autoimmune disorders such as Sjogren's disorder.
PCT/US2000/033220 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system WO2001041782A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP00984018A EP1237567B1 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system
AU20698/01A AU783208B2 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system
CA002393688A CA2393688A1 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system
JP2001543126A JP2003516360A (en) 1999-12-09 2000-12-08 Method of administering cytokine to central nervous system and lymphatic system
IL15010900A IL150109A0 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system
AT00984018T ATE300952T1 (en) 1999-12-09 2000-12-08 METHOD FOR ADMINISTRATION OF ACTIVE INGREDIENTS INTO THE CENTRAL NERVOUS SYSTEM OR LYMPH SYSTEM
DE60021760T DE60021760T2 (en) 1999-12-09 2000-12-08 METHOD FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES IN THE CENTRAL NERVOUS SYSTEM OR LYMPHIC SYSTEM
NO20022731A NO20022731L (en) 1999-12-09 2002-06-07 Method of administering a cytokine to the central nervous system and the lymphatic system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20070899P 1999-12-09 1999-12-09
US60/200,708 1999-12-09

Publications (2)

Publication Number Publication Date
WO2001041782A2 WO2001041782A2 (en) 2001-06-14
WO2001041782A3 true WO2001041782A3 (en) 2002-01-17

Family

ID=22742853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033220 WO2001041782A2 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system

Country Status (10)

Country Link
US (3) US20010043915A1 (en)
EP (1) EP1237567B1 (en)
JP (1) JP2003516360A (en)
AT (1) ATE300952T1 (en)
AU (1) AU783208B2 (en)
CA (1) CA2393688A1 (en)
DE (1) DE60021760T2 (en)
IL (1) IL150109A0 (en)
NO (1) NO20022731L (en)
WO (1) WO2001041782A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6589591B1 (en) * 2001-07-10 2003-07-08 Baylor College Of Medicine Method for treating medical devices using glycerol and an antimicrobial agent
WO2003057274A2 (en) * 2001-12-28 2003-07-17 Genzyme Corporation Bioresorbable foam packing device and use thereof
DE60316407T2 (en) * 2002-02-06 2008-06-19 Ares Trading S.A. TUMOR NEKROSIS FACTOR IN COMBINATION WITH INTERFERON TO TREAT AND / OR PREVENT A DEMYELINATING DISEASE
US20070004743A1 (en) * 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US8524899B2 (en) 2003-03-04 2013-09-03 California Institute Of Technology Alternative heterocycles for DNA recognition
US20070110715A1 (en) * 2003-03-19 2007-05-17 Ares Trading S.A. Treatment of alzheimer's disease
FR2864901B1 (en) * 2004-01-09 2007-10-05 Philippe Perovitch COMPOSITION FOR THE TREATMENT IN CONTACT WITH HYPOSIALIES, INCLUDING PILOCARPINE AND MULTIPLE EFFECTS
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
WO2005120551A1 (en) * 2004-06-07 2005-12-22 Nastech Pharmaceutical Company Inc. Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
CA2607806A1 (en) * 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
CA2620364A1 (en) * 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP1915986A1 (en) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US9808509B2 (en) * 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US8221358B2 (en) * 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (en) 2008-05-19 2020-02-12 Advaxis Inc Double administration system for heterologous antigens comprising a recombinant Listeria strain attenuated by the dal / dat mutation and the ActA deletion comprising a nucleic acid molecule encoding a listeriolysin fusion protein O - prostate specific antigen
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2310030A4 (en) 2008-06-13 2013-08-14 Wisconsin Alumni Res Found Novel antiviral peptides against influenza virus
JP2011524372A (en) 2008-06-13 2011-09-01 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション A novel peptide adjuvant for influenza vaccination
US20100106132A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising superior and inferior covers
US20100106136A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug delivery device with sliding cartridge
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
WO2010068564A1 (en) * 2008-12-11 2010-06-17 Merck Sharp & Dohme Corp. Method for treating alzheimer's disease and related conditions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
BRPI1012635A2 (en) 2009-03-27 2016-06-21 Academia Sinica "methods and compositions for virus immunization"
US20120189581A1 (en) 2009-07-24 2012-07-26 Schultz-Cherry Stacey L Use of toxoplasma and derived compositions to prevent or treat microbial infections
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
FR2962335B1 (en) * 2010-07-12 2013-01-18 Cll Pharma USE OF PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
CN103282048B (en) 2010-10-01 2017-05-17 宾夕法尼亚大学理事会 The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
BR112013022249B8 (en) 2011-03-03 2022-10-25 Impel Neuropharma Inc NASAL DRUG DISTRIBUTION DEVICE
CN103687611A (en) 2011-03-11 2014-03-26 阿德瓦希斯公司 Listeria-based adjuvants
CN107376071B (en) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 Nozzle for delivering a compound to the upper olfactory region of a user
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
CN107737100A (en) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 The administration of Benzodiazepine composition
WO2012174481A1 (en) 2011-06-15 2012-12-20 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
EP2822600A4 (en) 2012-03-09 2016-04-06 Univ Northeastern Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
US9033912B2 (en) 2012-03-28 2015-05-19 Warsaw Orthopedic, Inc. Drug delivery system
US20130280297A1 (en) 2012-04-11 2013-10-24 Lori Neal Use of toxoplasma gene products to prevent or treat microbial infections
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
JP2016520378A (en) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド Medical unit dose container
KR20160010526A (en) 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 Adeno-associated virus mediated gene transfer to the central nervous system
US9901684B2 (en) 2013-10-17 2018-02-27 Warsaw Orthopedic, Inc. Drug delivery device with retaining member
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
US20170119851A1 (en) 2014-05-19 2017-05-04 Novartis Ag Methods of treating anorexia
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
USD809652S1 (en) 2014-07-25 2018-02-06 Warsaw Orthopedic, Inc. Drug delivery device
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
LT3242676T (en) 2015-01-07 2024-01-25 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
KR20230125339A (en) 2016-04-15 2023-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Gene therapy for treating mucopolysaccharidosis type ii
USD802756S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
CN106620656A (en) * 2017-03-03 2017-05-10 上海唯科生物制药有限公司 Tumor necrosis factor-containing sublingual preparation and preparation method thereof
KR20200044982A (en) 2017-09-19 2020-04-29 어드박시스, 인크. Composition and method for lyophilization of bacteria or Listeria strains
JP7449223B2 (en) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Gene therapy to treat mucopolysaccharidosis type II
JP6941224B2 (en) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー Intranasal epinephrine preparations and methods for the treatment of the disease
US20210121545A1 (en) 2018-06-13 2021-04-29 Wisconsin Alumni Research Foundation (Warf) Toxoplasma gondii vaccine
SG11202107019VA (en) 2019-01-03 2021-07-29 Impel Neuropharma Inc Nasal drug delivery device
WO2022215036A1 (en) 2021-04-08 2022-10-13 Vaxthera Sas Coronavirus vaccine comprising a mosaic protein
CA3233861A1 (en) 2021-10-19 2023-04-27 Odyssey Health, Inc. Breath-powered nasal devices for treatment of traumatic brain injury (tbi), including concussion, and methods and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
WO1997041884A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Method of treatment
WO2000033814A2 (en) * 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462985A (en) 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4497795A (en) 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
SU1139444A1 (en) 1982-12-15 1985-02-15 Iretskij Andrej N Method of administering neurotropic and hormonal preparations
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
GB8918264D0 (en) * 1989-08-10 1989-09-20 Furnell David Rotary display unit
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
DK0647137T3 (en) * 1992-06-22 2008-12-08 State Of Oregon Through Oregon Glycine receptor antagonists and their use
JPH0741428A (en) 1993-07-30 1995-02-10 Teijin Ltd Peptide or protein medicine transnasal-transpulmonary preparation
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5675942A (en) * 1995-08-28 1997-10-14 Crawford; Van Wall panel alignment device and spacer
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
WO1997041884A1 (en) * 1996-05-09 1997-11-13 Pharma Pacific Pty. Ltd. Method of treatment
WO2000033814A2 (en) * 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system

Also Published As

Publication number Publication date
EP1237567B1 (en) 2005-08-03
DE60021760D1 (en) 2005-09-08
US20060159626A1 (en) 2006-07-20
JP2003516360A (en) 2003-05-13
IL150109A0 (en) 2002-12-01
AU783208B2 (en) 2005-10-06
DE60021760T2 (en) 2006-06-08
US20010043915A1 (en) 2001-11-22
EP1237567A2 (en) 2002-09-11
NO20022731D0 (en) 2002-06-07
US6991785B2 (en) 2006-01-31
ATE300952T1 (en) 2005-08-15
NO20022731L (en) 2002-08-08
AU2069801A (en) 2001-06-18
CA2393688A1 (en) 2001-06-14
WO2001041782A2 (en) 2001-06-14
US20020141971A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
WO2001041782A3 (en) Method for administering a cytokine to the central nervous system and the lymphatic system
WO2005000215A3 (en) Methods for treating pain
JP2003516360A5 (en)
WO2003002596A3 (en) Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
WO2000033814A3 (en) Method for administering agents to the central nervous system
ATE435917T1 (en) AAV VECTORS FOR PRODUCING THE DRUGS FOR CONVECTION-ENHANCED ADMINISTRATION
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
DE60203692T2 (en) LATENCY ASSOCIATED PEPTIDES OF TGF-BETA TO LATE PHARMACEUTICALLY ACTIVE PROTEINS
BR9814458A (en) Compound, pharmaceutical composition and method of treating affective disorders
AU4331400A (en) Neurotrophic substituted pyrimidines
GR3022060T3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
SG52443A1 (en) Methods and compositions for the treatment of disease with interferon while reducing sid effects
EP2359855A3 (en) Methods of administering anti-TNFalpha antibodies
AU2049500A (en) Administration of neurotrophic agents to the central nervous system
WO2003063573A3 (en) Method for treating diseases with omega interferon
MY118414A (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
EP1413299A3 (en) Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function
WO2003045978A3 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
CA2374997A1 (en) Il6ril6 chimera for the treatment of neurodegenerative diseases
AU1909995A (en) Co-administration of interleukin-3 mutant polypeptides with csf's for multi-lineage hematopoietic cell production
CA2463935A1 (en) Methods for treating multiple sclerosis
GB9930419D0 (en) Replication incompetent herpes virus vectors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2393688

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 150109

Country of ref document: IL

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 543126

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 20698/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519843

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000984018

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000984018

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 519843

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519843

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2000984018

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 20698/01

Country of ref document: AU